Regorafenib Reactions 1680, p295 - 2 Dec 2017 Various toxicities: 10 case reports A retrospective study described 10 patients (including a 40-year-old woman) [ages and sexes of other patients not stated], who developed anaemia, anorexia, diarrhoea, hand- foot skin reaction, hypertension, hypoalbuminaemia, hypophosphataemia, hypothyroidism, malaise, neutropenia, proteinuria, thrombocytopenia, weight loss or increased lipase during treatment with regorafenib [time to reactions onsets not stated]. All the ten patients had a medical history of unresectable hepatocellular carcinoma. All the patients had undergone a prior treatment with sorafenib which was discontinued due to disease progression. Later, all the ten patients were started on treatment with oral regorafenib 160mg once daily for 3 weeks in each 4 week cycle with best supportive care. Subsequently, they developed grade 2 hypoalbuminaemia, grade 3 hypophosphataemia, grade 2 weight loss and grade 2 anorexia (1 patient); grade 3 hand-foot skin reaction and grade 3 hypertension (1 patient); grade 2 proteinuria and grade 2 malaise (1 patient); grade 2 anorexia and grade 3 lipase increased (1 patient); grade 3 proteinuria, grade 3 hypertension, grade 2 hypothyroidism, grade 2 anorexia, grade 2 anaemia, grade 3 hypophosphataemia or grade 2 thrombocytopenia (1 patient); grade 2 diarrhoea and grade 2 anorexia (1 patient); grade 2 malaise and grade 1 anorexia (1 patient); grade 2 thrombocytopenia or grade 3 neutropenia (1 patient); grade 1 hand-foot skin reaction, grade 2 malaise, grade 3 thrombocytopenia and grade 3 neutropenia (1 patient), and one patient developed grade 3 hand-foot skin reaction. All treatment-related adverse events were improved by the reduction or interruption of regorafenib treatment. Author comment: "In this study, we investigated the efficacy and safety of regorafenib". "The drug-related adverse events are summarized. . . Grade 3 hypophosphatemia without symptoms was observed in 2 patients, grade 2 anorexia was observed in 5 patients, and grade 3 neutropenia was observed in 2 patients. Grade 2 and grade 3 thrombocytopenia were observed in 2 and 3 patients, respectively." Ueshima K, et al. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience. Digestive Diseases 35: 611-617, No. 6, Oct 2017. Available from: URL: - Japan 803285178 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial